Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARSHAD M KHANANI

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1295929511
CMS profile
240860
Location
RENO, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$271,029.92

172 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARSHAD M KHANANI

NPI 1295929511 · CMS profile ID 240860

Allopathic & Osteopathic Physicians / Ophthalmology

RENO, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295929511?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARSHAD M KHANANI, NPI 1295929511, CMS profile ID 240860. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295929511?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ARSHAD M KHANANI, NPI 1295929511, CMS profile ID 240860. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295929511?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ARSHAD M KHANANI, NPI 1295929511, CMS profile ID 240860, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 172 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1295929511?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

172 matching records · $271,029.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 172 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 172.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bausch & Lomb Americas Inc. $4.7909/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460493 CMS
Bausch & Lomb Americas Inc. $6.9409/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460497 CMS
BioTissue Holdings, Inc. $21.9409/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932247947 CMS
Novartis Pharma AG $2,150.0009/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941754245 CMS
F. Hoffmann-La Roche AG $59.1509/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808791 CMS
F. Hoffmann-La Roche AG $4,620.0009/02/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808793 CMS
F. Hoffmann-La Roche AG $13,390.6009/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808731 CMS
F. Hoffmann-La Roche AG $55.6009/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808733 CMS
F. Hoffmann-La Roche AG $534.7009/01/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808735 CMS
F. Hoffmann-La Roche AG $8,930.0009/01/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808737 CMS
Genentech, Inc. $6,720.0009/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808659 CMS
ABBVIE INC. $4,400.0008/29/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893059611 CMS
ABBVIE INC. $1,100.0008/29/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893059613 CMS
EyePoint Pharmaceuticals US, Inc. $24.3908/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932990691 CMS
ABBVIE INC. $7.8108/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893059609 CMS
Genentech USA, Inc. $2,355.0008/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950809999 CMS
Genentech, Inc. $11,264.0008/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950809979 CMS
Genentech, Inc. $2,041.0008/16/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950810241 CMS
Apellis Pharmaceuticals, Inc. $317.0808/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964256299 CMS
Apellis Pharmaceuticals, Inc. $39.7108/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964256301 CMS
Genentech USA, Inc. $3.2108/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950706975 CMS
Genentech USA, Inc. $22.1208/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950706977 CMS
ABBVIE INC. $10,000.0008/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893059607 CMS
Bausch & Lomb Americas Inc. $9.7408/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460489 CMS
Genentech USA, Inc. $24.6308/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950706981 CMS
Genentech, Inc. $26.9808/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950705569 CMS
Apellis Pharmaceuticals, Inc. $5,915.0007/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964256045 CMS
Apellis Pharmaceuticals, Inc. $682.5007/28/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964256931 CMS
Genentech USA, Inc. $11.8607/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950697077 CMS
Bausch & Lomb Americas Inc. $1,650.0007/27/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460521 CMS
Bausch & Lomb Americas Inc. $93.7307/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 957460517 CMS
Genentech USA, Inc. $196.2707/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950654645 CMS
Genentech USA, Inc. $298.0207/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950654649 CMS
Ocular Therapeutix, Inc. $36.4707/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954482673 CMS
ABBVIE INC. $2.3607/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893059605 CMS
Genentech USA, Inc. $101.2507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658723 CMS
Genentech, Inc. $120.8507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950659703 CMS
ABBVIE INC. $142.9007/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893059603 CMS
Genentech USA, Inc. $7,560.0007/12/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950658784 CMS
Genentech, Inc. $147.1307/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950766071 CMS
Novartis Pharmaceuticals Corporation $41.2407/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893831437 CMS
Roche Products Limited $27.8107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808755 CMS
Roche Products Limited $3,500.0007/11/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808757 CMS
F. Hoffmann-La Roche AG $2,310.0007/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808159 CMS
F. Hoffmann-La Roche AG $3,780.0007/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950808163 CMS
Genentech USA, Inc. $17.0507/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950710639 CMS
Genentech USA, Inc. $1.0306/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950714335 CMS
Apellis Pharmaceuticals, Inc. $17.5106/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 964259453 CMS
Genentech USA, Inc. $150.0006/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950668865 CMS
Biogen, Inc. $29.2306/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923459119 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $326,970.34 308
PY2020 $194,118.56 127
PY2021 $198,297.67 146
PY2022 $271,029.92 172
PY2023 $285,497.84 147
PY2024 $312,928.68 203
PY2025 $424,127.07 228

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $39,148.27 18
PY2025 Principal investigator $9,440,296.74 794
PY2024 Recipient $34,748.66 38
PY2024 Principal investigator $5,811,402.38 536
PY2023 Recipient $35,655.81 9
PY2023 Principal investigator $6,631,631.17 453
PY2022 Recipient $6,696.00 7
PY2022 Principal investigator $7,057,542.40 316
PY2021 Recipient $22,062.69 14
PY2021 Principal investigator $6,270,986.55 250
PY2020 Recipient $22,048.81 12
PY2020 Principal investigator $6,171,987.30 141
PY2019 Principal investigator $2,437,713.74 67

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

812 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771937
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239503
Principal investigator 1 Ocular Therapeutix, Inc. $3,939.90 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239505
Principal investigator 1 Ocular Therapeutix, Inc. $49,562.76 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239507
Principal investigator 1 Ocular Therapeutix, Inc. $51,821.29 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239509
Principal investigator 1 Ocular Therapeutix, Inc. $9,629.80 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239511
Principal investigator 1 Roche TCRC, Inc. $20,388.00 12/31/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655915
Principal investigator 1 Ocular Therapeutix, Inc. $16,988.30 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239489
Principal investigator 1 Ocular Therapeutix, Inc. $3,850.00 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239491
Principal investigator 1 Ocular Therapeutix, Inc. $23,870.00 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239493
Principal investigator 1 Ocular Therapeutix, Inc. $4,020.40 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239495
Principal investigator 1 Ocular Therapeutix, Inc. $980.00 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239497
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239499
Principal investigator 1 Ocular Therapeutix, Inc. $2,520.00 12/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239501
Principal investigator 1 Ocular Therapeutix, Inc. $133,824.60 12/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239481
Principal investigator 1 Ocular Therapeutix, Inc. $48,288.20 12/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239483
Principal investigator 1 Ocular Therapeutix, Inc. $96,352.20 12/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239485
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 12/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239487
Principal investigator 1 Genentech, Inc. $40,216.85 12/22/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599758
Principal investigator 1 Genentech, Inc. $4,185.00 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211655824
Principal investigator 1 Genentech, Inc. $136.00 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211655831
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814771
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814777
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814782
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814789
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814797
Principal investigator 1 KYOWA KIRIN, INC. $6,892.47 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814805
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814816
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814824
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814829
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814837
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814845
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 12/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814852
Principal investigator 1 Ocular Therapeutix, Inc. $227,476.20 12/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239477
Principal investigator 1 Ocular Therapeutix, Inc. $3,788.08 12/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239479
Principal investigator 1 SANOFI US SERVICES INC. $55,579.48 12/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107505
Principal investigator 1 Roche TCRC, Inc. $9,396.70 12/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655894
Principal investigator 1 Ocular Therapeutix, Inc. $21,559.66 12/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239475
Principal investigator 1 SANOFI US SERVICES INC. $8,437.14 12/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107471
Principal investigator 1 SANOFI US SERVICES INC. $18,970.39 12/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107489
Principal investigator 1 Roche TCRC, Inc. $5,423.80 12/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655902
Principal investigator 1 Janssen Research & Development, LLC $274.00 12/15/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427180
Principal investigator 1 Janssen Research & Development, LLC $18,275.00 12/15/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427211
Principal investigator 1 Janssen Research & Development, LLC $1,274.00 12/15/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427238
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239447
Principal investigator 1 Genentech, Inc. $5,170.00 12/11/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599724
Principal investigator 1 Genentech, Inc. $11,240.00 12/11/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599754
Principal investigator 1 Genentech, Inc. $149.00 12/10/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211655819
Principal investigator 1 Genentech, Inc. $3,698.00 12/10/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211655828
Principal investigator 1 Ocular Therapeutix, Inc. $42,238.80 12/10/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239473
Principal investigator 1 Genentech, Inc. $2,070.00 12/09/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599729
Principal investigator 1 Genentech, Inc. $18,506.09 12/09/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599745
Principal investigator 1 Genentech, Inc. $257,090.00 12/08/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599872
Principal investigator 1 Roche TCRC, Inc. $5,119.00 12/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655898
Principal investigator 1 Roche TCRC, Inc. $6,895.42 12/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655906
Principal investigator 1 Ocular Therapeutix, Inc. $2,660.00 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239457
Principal investigator 1 Ocular Therapeutix, Inc. $6,081.80 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239459
Principal investigator 1 Ocular Therapeutix, Inc. $24,962.83 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239461
Principal investigator 1 Ocular Therapeutix, Inc. $6,085.15 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239463
Principal investigator 1 Ocular Therapeutix, Inc. $11,397.45 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239465
Principal investigator 1 Ocular Therapeutix, Inc. $12,320.00 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239467
Principal investigator 1 Ocular Therapeutix, Inc. $6,930.00 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239469
Principal investigator 1 Ocular Therapeutix, Inc. $1,540.00 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239471
Principal investigator 1 Roche TCRC, Inc. $3,700.00 12/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655857
Principal investigator 1 Ocular Therapeutix, Inc. $29,338.45 12/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239453
Principal investigator 1 Ocular Therapeutix, Inc. $23.91 12/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239455
Principal investigator 1 Genentech, Inc. $1,199.00 12/01/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599733
Principal investigator 1 Genentech, Inc. $8,283.00 12/01/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599736
Principal investigator 1 Genentech, Inc. $1,341.36 12/01/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599741
Principal investigator 1 Genentech, Inc. $4,242.89 12/01/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599749
Principal investigator 1 Genentech, Inc. $2,355.00 12/01/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599764
Principal investigator 1 Ocular Therapeutix, Inc. $11,633.02 12/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239449
Principal investigator 1 Ocular Therapeutix, Inc. $3,850.00 12/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239451
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 11/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814301
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 11/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221814308
Principal investigator 1 Genentech, Inc. $1,303.26 11/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599714
Principal investigator 1 Genentech, Inc. $20,350.36 11/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599858
Principal investigator 1 Janssen Research & Development, LLC $1,456.00 11/24/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1175427315
Principal investigator 1 Janssen Research & Development, LLC $1,274.00 11/24/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427337
Principal investigator 1 Genentech, Inc. $17,635.56 11/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599719
Principal investigator 1 Ocular Therapeutix, Inc. $140.00 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239433
Principal investigator 1 Ocular Therapeutix, Inc. $350.00 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239435
Principal investigator 1 Ocular Therapeutix, Inc. $97,889.40 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239437
Principal investigator 1 Ocular Therapeutix, Inc. $116,291.70 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239439
Principal investigator 1 Ocular Therapeutix, Inc. $9,000.00 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239441
Principal investigator 1 Ocular Therapeutix, Inc. $47,964.06 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239443
Principal investigator 1 Ocular Therapeutix, Inc. $8,425.00 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239445
Principal investigator 1 SANOFI US SERVICES INC. $215.09 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107466
Principal investigator 1 SANOFI US SERVICES INC. $44,746.94 11/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107483
Principal investigator 1 ABBVIE INC. $6,564.16 11/20/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202525086
Principal investigator 1 Genentech, Inc. $6,066.54 11/20/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599868
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 11/19/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771939
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 11/19/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771941
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 11/19/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771943
Principal investigator 1 Boehringer Ingelheim International GmbH $43.70 11/19/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771945
Principal investigator 1 Genentech, Inc. $71,528.00 11/19/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211599494
Principal investigator 1 Ocular Therapeutix, Inc. $3,150.00 11/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239429
Principal investigator 1 Ocular Therapeutix, Inc. $6,685.00 11/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239431
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 11/18/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771933
Principal investigator 1 Boehringer Ingelheim International GmbH $95.01 11/18/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771935
Principal investigator 1 Genentech, Inc. $17,172.60 11/14/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599693
Principal investigator 1 Ocular Therapeutix, Inc. $36,145.54 11/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239425
Principal investigator 1 Ocular Therapeutix, Inc. $20,040.87 11/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239427
Principal investigator 1 Roche TCRC, Inc. $3,200.00 11/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655910
Principal investigator 1 KYOWA KIRIN, INC. $411.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814104
Principal investigator 1 KYOWA KIRIN, INC. $750.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814112
Principal investigator 1 KYOWA KIRIN, INC. $15,138.50 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814121
Principal investigator 1 KYOWA KIRIN, INC. $1,410.25 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814129
Principal investigator 1 KYOWA KIRIN, INC. $2,055.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814138
Principal investigator 1 KYOWA KIRIN, INC. $1,541.25 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814147
Principal investigator 1 KYOWA KIRIN, INC. $645.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814157
Principal investigator 1 KYOWA KIRIN, INC. $3,750.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814165
Principal investigator 1 KYOWA KIRIN, INC. $2,329.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814170
Principal investigator 1 KYOWA KIRIN, INC. $13,357.50 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814178
Principal investigator 1 KYOWA KIRIN, INC. $24,660.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814187
Principal investigator 1 KYOWA KIRIN, INC. $58.16 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814196
Principal investigator 1 KYOWA KIRIN, INC. $1,720.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814206
Principal investigator 1 KYOWA KIRIN, INC. $568.68 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814214
Principal investigator 1 KYOWA KIRIN, INC. $13,700.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814221
Principal investigator 1 KYOWA KIRIN, INC. $2,740.00 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814231
Principal investigator 1 KYOWA KIRIN, INC. $1,438.50 11/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814239
Principal investigator 1 Ocular Therapeutix, Inc. $1,260.00 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239413
Principal investigator 1 Ocular Therapeutix, Inc. $7,334.45 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239415
Principal investigator 1 Ocular Therapeutix, Inc. $3,220.00 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239417
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239419
Principal investigator 1 Ocular Therapeutix, Inc. $11,043.68 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239421
Principal investigator 1 Ocular Therapeutix, Inc. $539.00 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239423
Principal investigator 1 SANOFI US SERVICES INC. $1,987.19 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107511
Principal investigator 1 SANOFI US SERVICES INC. $3,007.46 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107516
Principal investigator 1 SANOFI US SERVICES INC. $205.50 11/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107531
Principal investigator 1 ABBVIE INC. $4,060.96 11/11/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202523791
Principal investigator 1 Genentech, Inc. $4,900.00 11/10/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599865
Principal investigator 1 Genentech, Inc. $4,400.00 11/07/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599861
Principal investigator 1 Ocular Therapeutix, Inc. $1,500.00 11/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239409
Principal investigator 1 Ocular Therapeutix, Inc. $4,060.00 11/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239411
Principal investigator 1 SANOFI US SERVICES INC. $959.00 11/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107456
Principal investigator 1 SANOFI US SERVICES INC. $1,810.68 11/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107461
Principal investigator 1 Genentech, Inc. $68.00 11/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655801
Principal investigator 1 Genentech, Inc. $60,987.00 11/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655807
Principal investigator 1 Genentech, Inc. $689.00 11/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655811
Principal investigator 1 Genentech, Inc. $2,400.00 11/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655815
Principal investigator 1 KYOWA KIRIN, INC. $3,000.00 11/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221814090
Principal investigator 1 SANOFI US SERVICES INC. $1,370.00 11/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226107478
Principal investigator 1 Janssen Research & Development, LLC $2,046.00 10/31/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427269
Principal investigator 1 Ocular Therapeutix, Inc. $327,398.40 10/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239407
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 10/28/2025 Non-covered Recipient Entity
Sierra Eye Associates-Primary Services Reno
A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI 1815368 in participants with center-involved diabetic macular edema No dispute reported 06/30/2026 1220771931
Principal investigator 1 KYOWA KIRIN, INC. $8,267.27 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812659
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812668
Principal investigator 1 KYOWA KIRIN, INC. $4,705.75 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812678
Principal investigator 1 KYOWA KIRIN, INC. $8,205.61 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812686
Principal investigator 1 KYOWA KIRIN, INC. $4,767.40 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812692
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812713
Principal investigator 1 KYOWA KIRIN, INC. $4,530.66 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812725
Principal investigator 1 KYOWA KIRIN, INC. $4,705.75 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812734
Principal investigator 1 KYOWA KIRIN, INC. $4,767.40 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812741
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812749
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812757
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812765
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812775
Principal investigator 1 KYOWA KIRIN, INC. $8,267.27 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812790
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812798
Principal investigator 1 KYOWA KIRIN, INC. $4,767.40 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812805
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812812
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812819
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812825
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812834
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812841
Principal investigator 1 KYOWA KIRIN, INC. $6,892.47 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812848
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812862
Principal investigator 1 KYOWA KIRIN, INC. $8,267.27 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812869
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812878
Principal investigator 1 KYOWA KIRIN, INC. $8,267.27 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812885
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812891
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812901
Principal investigator 1 KYOWA KIRIN, INC. $8,267.27 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812908
Principal investigator 1 KYOWA KIRIN, INC. $2,051.71 10/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221812924
Principal investigator 1 Roche TCRC, Inc. $13,269.00 10/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
ENTRY INTO HUMAN OF RO7497372 IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655890
Principal investigator 1 Genentech, Inc. $5,152.00 10/22/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599850
Principal investigator 1 Genentech, Inc. $19,166.80 10/22/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599853
Principal investigator 1 Genentech, Inc. $272.00 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655763
Principal investigator 1 Genentech, Inc. $6,549.00 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655794
Principal investigator 1 KYOWA KIRIN, INC. $68.50 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811386
Principal investigator 1 KYOWA KIRIN, INC. $102.75 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811394
Principal investigator 1 KYOWA KIRIN, INC. $890.50 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811401
Principal investigator 1 KYOWA KIRIN, INC. $137.00 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811413
Principal investigator 1 KYOWA KIRIN, INC. $10,081.83 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811422
Principal investigator 1 KYOWA KIRIN, INC. $2,571.49 10/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811428
Principal investigator 1 Ocular Therapeutix, Inc. $89,060.30 10/22/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239403
Principal investigator 1 Ocular Therapeutix, Inc. $292,851.00 10/22/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239405
Principal investigator 1 Genentech, Inc. $18,129.00 10/17/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599698
Principal investigator 1 Genentech, Inc. $5,890.53 10/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655760
Principal investigator 1 Genentech, Inc. $69.00 10/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655768
Principal investigator 1 Genentech, Inc. $102.00 10/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655777
Principal investigator 1 Genentech, Inc. $1,097.00 10/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655785
Principal investigator 1 Genentech, Inc. $3,905.00 10/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655796
Principal investigator 1 Ocular Therapeutix, Inc. $3,500.00 10/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239399
Principal investigator 1 Ocular Therapeutix, Inc. $38,765.20 10/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239401
Principal investigator 1 Genentech, Inc. $11,251.75 10/16/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211599485
Principal investigator 1 Genentech, Inc. $3,595.63 10/16/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211599490
Principal investigator 1 Genentech, Inc. $3,762.00 10/16/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599707
Principal investigator 1 Genentech, Inc. $16,156.00 10/15/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655789
Principal investigator 1 Ocular Therapeutix, Inc. $3,614.52 10/15/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239329
Principal investigator 1 ABBVIE INC. $5,425.20 10/14/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202516761
Principal investigator 1 Janssen Research & Development, LLC $2,096.83 10/13/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427252
Principal investigator 1 Janssen Research & Development, LLC $1,365.00 10/13/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427284
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239513
Principal investigator 1 Genentech, Inc. $16,568.40 10/09/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599703
Principal investigator 1 Ocular Therapeutix, Inc. $3,623.68 10/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239391
Principal investigator 1 Ocular Therapeutix, Inc. $7,462.98 10/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239393
Principal investigator 1 Ocular Therapeutix, Inc. $4,001.30 10/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239395
Principal investigator 1 Ocular Therapeutix, Inc. $7,992.98 10/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239397
Recipient F. Hoffmann-La Roche AG $11,872.00 10/06/2025 Covered Recipient Physician OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211534710
Principal investigator 1 Genentech, Inc. $165.00 10/06/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599683
Principal investigator 1 KYOWA KIRIN, INC. $500.00 10/06/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221811138
Principal investigator 1 KYOWA KIRIN, INC. $1,746.75 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811037
Principal investigator 1 KYOWA KIRIN, INC. $2,329.00 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811045
Principal investigator 1 KYOWA KIRIN, INC. $205.50 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811054
Principal investigator 1 KYOWA KIRIN, INC. $4,932.00 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811063
Principal investigator 1 KYOWA KIRIN, INC. $3,490.00 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811071
Principal investigator 1 KYOWA KIRIN, INC. $66.73 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811081
Principal investigator 1 KYOWA KIRIN, INC. $18,000.00 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811089
Principal investigator 1 KYOWA KIRIN, INC. $15,138.50 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811096
Principal investigator 1 KYOWA KIRIN, INC. $28,770.00 10/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221811104
Principal investigator 1 Genentech, Inc. $18,214.00 10/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655772
Principal investigator 1 Genentech, Inc. $68.00 10/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655780
Principal investigator 1 Ocular Therapeutix, Inc. $20,040.00 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239377
Principal investigator 1 Ocular Therapeutix, Inc. $17,207.36 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239379
Principal investigator 1 Ocular Therapeutix, Inc. $3,483.68 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239381
Principal investigator 1 Ocular Therapeutix, Inc. $15,397.43 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239383
Principal investigator 1 Ocular Therapeutix, Inc. $20,954.66 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239385
Principal investigator 1 Ocular Therapeutix, Inc. $6,418.00 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239387
Principal investigator 1 Ocular Therapeutix, Inc. $4,195.00 10/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239389
Principal investigator 1 Genentech, Inc. $822.00 09/29/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599669
Principal investigator 1 KYOWA KIRIN, INC. $2,800.00 09/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810993
Principal investigator 1 Genentech, Inc. $16,760.00 09/26/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599674
Principal investigator 1 Genentech, Inc. $41,701.00 09/26/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599687
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/26/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427174
Principal investigator 1 Janssen Research & Development, LLC $708.00 09/26/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427200
Principal investigator 1 Janssen Research & Development, LLC $728.00 09/26/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427246
Principal investigator 1 KYOWA KIRIN, INC. $890.50 09/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810895
Principal investigator 1 KYOWA KIRIN, INC. $102.75 09/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810905
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 09/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810913
Principal investigator 1 KYOWA KIRIN, INC. $137.00 09/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810921
Principal investigator 1 KYOWA KIRIN, INC. $215.00 09/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810930
Principal investigator 1 KYOWA KIRIN, INC. $500.00 09/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810938
Principal investigator 1 Ocular Therapeutix, Inc. $32,631.04 09/26/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239373
Principal investigator 1 Ocular Therapeutix, Inc. $7,742.98 09/26/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239375
Principal investigator 1 Genentech, Inc. $1,400.00 09/24/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655662
Principal investigator 1 Ocular Therapeutix, Inc. $1,050.00 09/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239369
Principal investigator 1 Ocular Therapeutix, Inc. $1,050.00 09/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239371
Recipient F. Hoffmann-La Roche AG $644.00 09/19/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211534672
Recipient F. Hoffmann-La Roche AG $443.92 09/19/2025 Covered Recipient Physician OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211534706
Principal investigator 1 Genentech, Inc. $1,943.68 09/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655678
Principal investigator 1 Genentech, Inc. $1,165.00 09/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655697
Principal investigator 1 Genentech, Inc. $823.00 09/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655707
Principal investigator 1 Genentech, Inc. $14,022.00 09/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655722
Principal investigator 1 Genentech, Inc. $51.00 09/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655729
Principal investigator 1 Genentech, Inc. $69.00 09/17/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655738
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 09/15/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810596
Principal investigator 1 Genentech, Inc. $1,902.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655621
Principal investigator 1 Genentech, Inc. $1,165.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655627
Principal investigator 1 Genentech, Inc. $207.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655651
Principal investigator 1 Genentech, Inc. $3,535.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655682
Principal investigator 1 Genentech, Inc. $480.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655689
Principal investigator 1 Genentech, Inc. $102.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655693
Principal investigator 1 Genentech, Inc. $891.00 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655700
Principal investigator 1 Genentech, Inc. $1,987.19 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655742
Principal investigator 1 Genentech, Inc. $1,987.19 09/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655756
Principal investigator 1 Janssen Research & Development, LLC $708.00 09/12/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427186
Principal investigator 1 Janssen Research & Development, LLC $50.65 09/12/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427261
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 09/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239367
Principal investigator 1 Genentech, Inc. $4,388.00 09/10/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211599478
Principal investigator 1 KYOWA KIRIN, INC. $500.00 09/10/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810471
Principal investigator 1 KYOWA KIRIN, INC. $500.00 09/10/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810478
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 09/10/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221810486
Principal investigator 1 ABBVIE INC. $5,229.03 09/09/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202510350
Principal investigator 1 ABBVIE INC. $4,522.73 09/09/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202510352
Principal investigator 1 ABBVIE INC. $6,216.15 09/09/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202510364
Principal investigator 1 Ocular Therapeutix, Inc. $11,812.06 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239353
Principal investigator 1 Ocular Therapeutix, Inc. $32,410.40 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239355
Principal investigator 1 Ocular Therapeutix, Inc. $16,064.60 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239357
Principal investigator 1 Ocular Therapeutix, Inc. $20,461.04 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239359
Principal investigator 1 Ocular Therapeutix, Inc. $35,280.02 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239361
Principal investigator 1 Ocular Therapeutix, Inc. $910.00 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239363
Principal investigator 1 Ocular Therapeutix, Inc. $35,225.26 09/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239365
Principal investigator 1 Genentech, Inc. $9,000.00 09/04/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599676
Principal investigator 1 Genentech, Inc. $1,311.00 09/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655654
Principal investigator 1 Ocular Therapeutix, Inc. $880.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239331
Principal investigator 1 Ocular Therapeutix, Inc. $4,259.30 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239333
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239335
Principal investigator 1 Ocular Therapeutix, Inc. $18,360.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239337
Principal investigator 1 Ocular Therapeutix, Inc. $25,730.60 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239339
Principal investigator 1 Ocular Therapeutix, Inc. $3,290.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239341
Principal investigator 1 Ocular Therapeutix, Inc. $3,150.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239343
Principal investigator 1 Ocular Therapeutix, Inc. $3,353.55 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239345
Principal investigator 1 Ocular Therapeutix, Inc. $1,320.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239347
Principal investigator 1 Ocular Therapeutix, Inc. $266.17 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239349
Principal investigator 1 Ocular Therapeutix, Inc. $880.00 09/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239351
Principal investigator 1 ABBVIE INC. $29,468.70 09/02/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202507031
Principal investigator 1 KYOWA KIRIN, INC. $11,561.43 09/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221810434
Recipient F. Hoffmann-La Roche AG $565.91 08/29/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211534676
Principal investigator 1 Ocular Therapeutix, Inc. $69,426.00 08/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239327
Principal investigator 1 ABBVIE INC. $6,374.61 08/27/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506129
Principal investigator 1 ABBVIE INC. $1,294.65 08/27/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506147
Principal investigator 1 ABBVIE INC. $8,310.42 08/27/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506149
Principal investigator 1 ABBVIE INC. $19,493.73 08/27/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506193
Principal investigator 1 Genentech, Inc. $8,554.04 08/27/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599665
Principal investigator 1 Genentech, Inc. $13,019.86 08/27/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599680
Principal investigator 1 Ocular Therapeutix, Inc. $1,100.00 08/27/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239325
Principal investigator 1 Genentech, Inc. $9,000.00 08/22/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599689
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 08/22/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221809726
Principal investigator 1 Ocular Therapeutix, Inc. $350.00 08/22/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239321
Principal investigator 1 Ocular Therapeutix, Inc. $1,050.00 08/22/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239323
Principal investigator 1 Genentech, Inc. $4,672.00 08/20/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599846
Principal investigator 1 Genentech, Inc. $1,311.00 08/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655638
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239309
Principal investigator 1 Ocular Therapeutix, Inc. $23,260.00 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239311
Principal investigator 1 Ocular Therapeutix, Inc. $151,700.40 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239313
Principal investigator 1 Ocular Therapeutix, Inc. $2,377.00 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239315
Principal investigator 1 Ocular Therapeutix, Inc. $49,947.90 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239317
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239319
Principal investigator 1 Roche TCRC, Inc. $3,600.00 08/20/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655854
Principal investigator 1 Genentech, Inc. $25,041.00 08/15/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211599481
Principal investigator 1 Genentech, Inc. $11,334.00 08/15/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655665
Principal investigator 1 Genentech, Inc. $204.00 08/15/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655733
Principal investigator 1 Ocular Therapeutix, Inc. $13,020.00 08/15/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239307
Principal investigator 1 KYOWA KIRIN, INC. $6,000.00 08/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809582
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 08/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809594
Principal investigator 1 KYOWA KIRIN, INC. $1,048.69 08/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221809600
Principal investigator 1 KYOWA KIRIN, INC. $137.00 08/13/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221809527
Principal investigator 1 KYOWA KIRIN, INC. $890.50 08/13/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221809537
Principal investigator 1 KYOWA KIRIN, INC. $205.50 08/13/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221809544
Principal investigator 1 Ocular Therapeutix, Inc. $1,960.00 08/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239301
Principal investigator 1 Ocular Therapeutix, Inc. $4,000.00 08/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239303
Principal investigator 1 Ocular Therapeutix, Inc. $37,985.30 08/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239305
Principal investigator 1 SANOFI US SERVICES INC. $5,679.80 08/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085587
Principal investigator 1 SANOFI US SERVICES INC. $500.00 08/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085579
Principal investigator 1 Genentech, Inc. $1,010.00 08/06/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655657
Principal investigator 1 Ocular Therapeutix, Inc. $72.74 08/06/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239297
Principal investigator 1 Ocular Therapeutix, Inc. $233.60 08/06/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239299
Principal investigator 1 Janssen Research & Development, LLC $7,436.00 08/04/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427219
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808449
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808457
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808462
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808470
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808479
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808484
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808491
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808499
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808508
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808515
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808522
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808528
Principal investigator 1 KYOWA KIRIN, INC. $4,705.75 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808536
Principal investigator 1 KYOWA KIRIN, INC. $4,705.75 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808545
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808551
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808559
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808571
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808578
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808586
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808592
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808598
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808607
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808615
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808623
Principal investigator 1 KYOWA KIRIN, INC. $8,205.61 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808637
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808645
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808651
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808659
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808667
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 08/04/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221808675
Recipient F. Hoffmann-La Roche AG $533.33 08/01/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211534702
Principal investigator 1 Ocular Therapeutix, Inc. $15,429.11 08/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239295
Principal investigator 1 KYOWA KIRIN, INC. $3,482.61 07/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807760
Principal investigator 1 KYOWA KIRIN, INC. $3,482.61 07/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807768
Principal investigator 1 KYOWA KIRIN, INC. $5,844.42 07/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807777
Principal investigator 1 KYOWA KIRIN, INC. $3,390.14 07/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807783
Principal investigator 1 Ocular Therapeutix, Inc. $4,500.00 07/30/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239293
Recipient F. Hoffmann-La Roche AG $421.25 07/29/2025 Covered Recipient Physician Comparison of Diabetic Retinopathy Progression With 7 Field and Ultrawide Imaging in the Phase 3 YOSEMITE/RHINE Studies No dispute reported 06/30/2026 1211534718
Principal investigator 1 Genentech, Inc. $2,150.00 07/29/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599661
Principal investigator 1 Genentech, Inc. $10,415.65 07/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599827
Principal investigator 1 Genentech, Inc. $101,433.00 07/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599842
Principal investigator 1 Janssen Research & Development, LLC $11,688.00 07/28/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427234
Principal investigator 1 ABBVIE INC. $5,305.00 07/25/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499806
Principal investigator 1 ABBVIE INC. $3,263.83 07/25/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499808
Principal investigator 1 ABBVIE INC. $6,295.72 07/25/2025 Non-covered Recipient Entity
DURANT ET AL LTD
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499818
Principal investigator 1 Genentech, Inc. $7,869.00 07/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599824
Principal investigator 1 Genentech, Inc. $3,253.12 07/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599836
Principal investigator 1 Genentech, Inc. $25,331.00 07/25/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655647
Principal investigator 1 Genentech, Inc. $272.00 07/25/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655672
Principal investigator 1 Genentech, Inc. $6,942.00 07/25/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655686
Principal investigator 1 Ocular Therapeutix, Inc. $16,955.30 07/25/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239285
Principal investigator 1 Ocular Therapeutix, Inc. $8,317.65 07/25/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239287
Principal investigator 1 Ocular Therapeutix, Inc. $22,200.30 07/25/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239289
Principal investigator 1 Ocular Therapeutix, Inc. $1,657.40 07/25/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239291
Principal investigator 1 Genentech, Inc. $2,200.00 07/24/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599832
Principal investigator 1 Genentech, Inc. $1,851.00 07/23/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655669
Principal investigator 1 Genentech, Inc. $136.00 07/23/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655714
Principal investigator 1 KYOWA KIRIN, INC. $3,000.00 07/23/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221807170
Principal investigator 1 Ocular Therapeutix, Inc. $133,347.60 07/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239279
Principal investigator 1 Ocular Therapeutix, Inc. $151,258.50 07/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239281
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 07/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239283
Principal investigator 1 Genentech, Inc. $2,877.00 07/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599839
Principal investigator 1 Genentech, Inc. $24,770.00 07/18/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655703
Principal investigator 1 Genentech, Inc. $138.00 07/18/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655718
Principal investigator 1 Genentech, Inc. $2,151.00 07/18/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655745
Principal investigator 1 Genentech, Inc. $153.00 07/18/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655749
Principal investigator 1 Genentech, Inc. $686.00 07/18/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655752
Principal investigator 1 Ocular Therapeutix, Inc. $2,285.46 07/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239271
Principal investigator 1 Ocular Therapeutix, Inc. $2,200.00 07/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239273
Principal investigator 1 Ocular Therapeutix, Inc. $1,500.00 07/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239275
Principal investigator 1 Ocular Therapeutix, Inc. $695.38 07/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239277
Principal investigator 1 SANOFI US SERVICES INC. $225.00 07/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085575
Principal investigator 1 Genentech, Inc. $44,356.00 07/16/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655634
Principal investigator 1 Ocular Therapeutix, Inc. $3,561.15 07/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239261
Principal investigator 1 Ocular Therapeutix, Inc. $3,701.15 07/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239263
Principal investigator 1 Ocular Therapeutix, Inc. $17,590.00 07/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239265
Principal investigator 1 Ocular Therapeutix, Inc. $20,435.30 07/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239267
Principal investigator 1 Ocular Therapeutix, Inc. $3,425.00 07/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239269
Principal investigator 1 KYOWA KIRIN, INC. $5,837.57 07/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806894
Principal investigator 1 Ocular Therapeutix, Inc. $4,477.00 07/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239259
Principal investigator 1 SANOFI US SERVICES INC. $46,719.74 07/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085583
Principal investigator 1 Genentech, Inc. $1,622.00 07/09/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655643
Principal investigator 1 Ocular Therapeutix, Inc. $500.00 07/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239253
Principal investigator 1 Ocular Therapeutix, Inc. $22.02 07/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239255
Principal investigator 1 Ocular Therapeutix, Inc. $277.00 07/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239257
Principal investigator 1 Genentech, Inc. $71,892.00 07/07/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599658
Principal investigator 1 Janssen Research & Development, LLC $274.00 07/07/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427126
Principal investigator 1 Janssen Research & Development, LLC $923.00 07/07/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427131
Principal investigator 1 Janssen Research & Development, LLC $7,436.00 07/04/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427323
Principal investigator 1 Ocular Therapeutix, Inc. $12,385.30 07/04/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239249
Principal investigator 1 Ocular Therapeutix, Inc. $7,404.38 07/04/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239251
Principal investigator 1 Janssen Research & Development, LLC $500.00 07/03/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427330
Principal investigator 1 KYOWA KIRIN, INC. $137.00 07/02/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806838
Principal investigator 1 KYOWA KIRIN, INC. $68.50 07/02/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806846
Principal investigator 1 KYOWA KIRIN, INC. $102.75 07/02/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806852
Principal investigator 1 KYOWA KIRIN, INC. $890.50 07/02/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806861
Principal investigator 1 Ocular Therapeutix, Inc. $101.94 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239235
Principal investigator 1 Ocular Therapeutix, Inc. $3,987.65 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239237
Principal investigator 1 Ocular Therapeutix, Inc. $1,500.00 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239239
Principal investigator 1 Ocular Therapeutix, Inc. $8.30 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239241
Principal investigator 1 Ocular Therapeutix, Inc. $6,006.00 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239243
Principal investigator 1 Ocular Therapeutix, Inc. $1,905.00 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239245
Principal investigator 1 Ocular Therapeutix, Inc. $74,008.20 07/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239247
Principal investigator 1 Genentech, Inc. $22,973.37 07/01/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Constance Faricimab in nAMD patients No dispute reported 06/30/2026 1211599470
Principal investigator 1 SANOFI US SERVICES INC. $300.00 07/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085560
Principal investigator 1 SANOFI US SERVICES INC. $300.00 07/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085563
Principal investigator 1 SANOFI US SERVICES INC. $150.00 07/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085567
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 07/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085571
Recipient F. Hoffmann-La Roche AG $306.36 06/30/2025 Covered Recipient Physician OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211534714
Principal investigator 1 KYOWA KIRIN, INC. $10,362.68 06/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806831
Recipient Ocular Therapeutix, Inc. $10,469.62 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229172
Principal investigator 1 KYOWA KIRIN, INC. $137.00 06/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806761
Principal investigator 1 KYOWA KIRIN, INC. $890.50 06/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806769
Principal investigator 1 KYOWA KIRIN, INC. $102.75 06/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221806777
Principal investigator 1 Roche TCRC, Inc. $3,750.00 06/26/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655842
Principal investigator 1 Roche TCRC, Inc. $3,833.50 06/26/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655850
Principal investigator 1 Genentech, Inc. $11,598.00 06/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599499
Principal investigator 1 Genentech, Inc. $35,110.00 06/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599503
Principal investigator 1 Genentech, Inc. $129,180.00 06/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599529
Principal investigator 1 Genentech, Inc. $2,192.00 06/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599533
Principal investigator 1 Genentech, Inc. $1,425.00 06/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599554
Principal investigator 1 Genentech, Inc. $500.00 06/25/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655551
Principal investigator 1 Genentech, Inc. $40,324.00 06/23/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599507
Principal investigator 1 Ocular Therapeutix, Inc. $22,110.00 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239189
Principal investigator 1 Ocular Therapeutix, Inc. $20,300.00 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239191
Principal investigator 1 Ocular Therapeutix, Inc. $5,796.00 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239193
Principal investigator 1 Ocular Therapeutix, Inc. $18,262.95 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239195
Principal investigator 1 Ocular Therapeutix, Inc. $3,993.15 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239197
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239199
Principal investigator 1 Ocular Therapeutix, Inc. $2,015.00 06/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239201
Principal investigator 1 Genentech, Inc. $9,565.00 06/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655560
Principal investigator 1 Genentech, Inc. $272.00 06/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655571
Principal investigator 1 Genentech, Inc. $171.00 06/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599521
Principal investigator 1 Genentech, Inc. $5,179.12 06/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599549
Principal investigator 1 Genentech, Inc. $25,949.34 06/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599771
Principal investigator 1 Genentech, Inc. $50,598.98 06/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599779
Principal investigator 1 Ocular Therapeutix, Inc. $2,490.00 06/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239177
Principal investigator 1 Ocular Therapeutix, Inc. $385,559.10 06/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239179
Principal investigator 1 Ocular Therapeutix, Inc. $3,573.15 06/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239181
Principal investigator 1 Ocular Therapeutix, Inc. $39,545.95 06/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239183
Principal investigator 1 Ocular Therapeutix, Inc. $6,790.80 06/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239185
Principal investigator 1 Ocular Therapeutix, Inc. $18.55 06/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239187
Principal investigator 1 Genentech, Inc. $9,345.63 06/17/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599789
Principal investigator 1 Genentech, Inc. $18,006.01 06/17/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599793
Principal investigator 1 Ocular Therapeutix, Inc. $10,150.00 06/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239175
Principal investigator 1 Genentech, Inc. $3,626.36 06/12/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599541
Principal investigator 1 Genentech, Inc. $6,553.00 06/11/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599516
Principal investigator 1 Genentech, Inc. $23,980.00 06/11/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599773
Principal investigator 1 Genentech, Inc. $500.00 06/11/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655609
Principal investigator 1 Ocular Therapeutix, Inc. $6,930.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239157
Principal investigator 1 Ocular Therapeutix, Inc. $11,602.03 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239159
Principal investigator 1 Ocular Therapeutix, Inc. $2,420.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239161
Principal investigator 1 Ocular Therapeutix, Inc. $4,500.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239163
Principal investigator 1 Ocular Therapeutix, Inc. $420.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239165
Principal investigator 1 Ocular Therapeutix, Inc. $3,807.19 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239167
Principal investigator 1 Ocular Therapeutix, Inc. $2,000.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239169
Principal investigator 1 Ocular Therapeutix, Inc. $4,690.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239171
Principal investigator 1 Ocular Therapeutix, Inc. $20,790.00 06/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239173
Principal investigator 1 Janssen Research & Development, LLC $15,132.00 06/09/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427161
Principal investigator 1 Janssen Research & Development, LLC $364.00 06/06/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427289
Principal investigator 1 Ocular Therapeutix, Inc. $32,340.00 06/06/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239153
Principal investigator 1 Ocular Therapeutix, Inc. $29,264.00 06/06/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239155
Principal investigator 1 SANOFI US SERVICES INC. $6,783.79 06/04/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085545
Principal investigator 1 Genentech, Inc. $21,540.57 06/02/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599545
Principal investigator 1 Genentech, Inc. $81,856.00 06/02/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599783
Principal investigator 1 Janssen Research & Development, LLC $182.00 06/02/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427138
Principal investigator 1 Janssen Research & Development, LLC $36.34 06/02/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427301
Principal investigator 1 KYOWA KIRIN, INC. $137.00 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806183
Principal investigator 1 KYOWA KIRIN, INC. $685.00 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806194
Principal investigator 1 KYOWA KIRIN, INC. $1,233.00 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806202
Principal investigator 1 KYOWA KIRIN, INC. $8,014.50 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806208
Principal investigator 1 KYOWA KIRIN, INC. $137.00 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806216
Principal investigator 1 KYOWA KIRIN, INC. $13,700.00 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806223
Principal investigator 1 KYOWA KIRIN, INC. $924.75 05/29/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221806231
Principal investigator 1 Genentech, Inc. $5,886.04 05/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599512
Principal investigator 1 Genentech, Inc. $5,886.04 05/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599537
Principal investigator 1 Genentech, Inc. $162.00 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655576
Principal investigator 1 Genentech, Inc. $3,812.00 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655590
Principal investigator 1 KYOWA KIRIN, INC. $137.00 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805901
Principal investigator 1 KYOWA KIRIN, INC. $10,396.93 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805911
Principal investigator 1 KYOWA KIRIN, INC. $102.75 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805921
Principal investigator 1 KYOWA KIRIN, INC. $4,789.52 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805927
Principal investigator 1 KYOWA KIRIN, INC. $68.50 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805937
Principal investigator 1 KYOWA KIRIN, INC. $890.50 05/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805946
Principal investigator 1 Ocular Therapeutix, Inc. $86,209.20 05/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239149
Principal investigator 1 Ocular Therapeutix, Inc. $30.42 05/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239151
Principal investigator 1 Genentech, Inc. $2,695.33 05/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599525
Principal investigator 1 Ocular Therapeutix, Inc. $10,895.00 05/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239137
Principal investigator 1 Ocular Therapeutix, Inc. $82.00 05/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239139
Principal investigator 1 Ocular Therapeutix, Inc. $17,326.00 05/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239141
Principal investigator 1 Ocular Therapeutix, Inc. $880.00 05/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239143
Principal investigator 1 Ocular Therapeutix, Inc. $8,707.19 05/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239145
Principal investigator 1 Ocular Therapeutix, Inc. $39,464.00 05/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239147
Principal investigator 1 Genentech, Inc. $1,392.07 05/20/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599619
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 05/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221805735
Principal investigator 1 KYOWA KIRIN, INC. $137.00 05/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805740
Principal investigator 1 KYOWA KIRIN, INC. $102.75 05/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805746
Principal investigator 1 KYOWA KIRIN, INC. $890.50 05/19/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221805756
Principal investigator 1 Genentech, Inc. $3,300.00 05/15/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599812
Principal investigator 1 Genentech, Inc. $1,345.76 05/14/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599633
Principal investigator 1 Genentech, Inc. $207.00 05/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655556
Principal investigator 1 Genentech, Inc. $3,097.24 05/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655581
Principal investigator 1 Genentech, Inc. $951.00 05/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655584
Principal investigator 1 Genentech, Inc. $685.00 05/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655598
Principal investigator 1 Genentech, Inc. $5,570.00 05/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655604
Principal investigator 1 Ocular Therapeutix, Inc. $3,530.00 05/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239127
Principal investigator 1 Ocular Therapeutix, Inc. $10,780.00 05/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239129
Principal investigator 1 Ocular Therapeutix, Inc. $18.83 05/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239131
Principal investigator 1 Ocular Therapeutix, Inc. $5,775.00 05/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239133
Principal investigator 1 Ocular Therapeutix, Inc. $16,698.76 05/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239135
Recipient F. Hoffmann-La Roche AG $668.00 05/11/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211534689
Principal investigator 1 Ocular Therapeutix, Inc. $10,134.38 05/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239117
Principal investigator 1 Ocular Therapeutix, Inc. $1,598.40 05/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239119
Principal investigator 1 Ocular Therapeutix, Inc. $8,795.00 05/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239121
Principal investigator 1 Ocular Therapeutix, Inc. $411.00 05/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239123
Principal investigator 1 Ocular Therapeutix, Inc. $11,297.78 05/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239125
Recipient F. Hoffmann-La Roche AG $335.71 05/08/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211534692
Principal investigator 1 Janssen Research & Development, LLC $1,274.00 05/08/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427167
Principal investigator 1 Roche TCRC, Inc. $2,840.00 05/08/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655838
Principal investigator 1 Ocular Therapeutix, Inc. $7,980.00 05/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239107
Principal investigator 1 Ocular Therapeutix, Inc. $2,520.00 05/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239109
Principal investigator 1 Ocular Therapeutix, Inc. $18,000.00 05/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239111
Principal investigator 1 Ocular Therapeutix, Inc. $9,248.00 05/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239113
Principal investigator 1 Ocular Therapeutix, Inc. $2,312.00 05/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239115
Recipient F. Hoffmann-La Roche AG $7,232.43 05/05/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211534681
Recipient F. Hoffmann-La Roche AG $266.56 05/05/2025 Covered Recipient Physician Faricimab DME Long Term Extension Rhone X No dispute reported 06/30/2026 1211534696
Principal investigator 1 Janssen Research & Development, LLC $215.00 05/02/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427151
Principal investigator 1 Genentech, Inc. $56,246.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655548
Principal investigator 1 Genentech, Inc. $11,332.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655564
Principal investigator 1 Genentech, Inc. $204.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655568
Principal investigator 1 Genentech, Inc. $23,362.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655594
Principal investigator 1 Genentech, Inc. $476.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655601
Principal investigator 1 Genentech, Inc. $7,643.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655612
Principal investigator 1 Genentech, Inc. $10,334.00 05/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655615
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 05/01/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085540
Principal investigator 1 Ocular Therapeutix, Inc. $62,943.30 04/30/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239103
Principal investigator 1 Ocular Therapeutix, Inc. $6,077.00 04/30/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239105
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221803880
Principal investigator 1 KYOWA KIRIN, INC. $4,055.96 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804004
Principal investigator 1 KYOWA KIRIN, INC. $137.00 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804035
Principal investigator 1 KYOWA KIRIN, INC. $102.75 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804043
Principal investigator 1 KYOWA KIRIN, INC. $7,490.47 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804049
Principal investigator 1 KYOWA KIRIN, INC. $3,390.14 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804057
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804065
Principal investigator 1 KYOWA KIRIN, INC. $8,491.67 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804074
Principal investigator 1 KYOWA KIRIN, INC. $4,672.46 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804082
Principal investigator 1 KYOWA KIRIN, INC. $800.00 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804090
Principal investigator 1 KYOWA KIRIN, INC. $890.50 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804098
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221804107
Principal investigator 1 KYOWA KIRIN, INC. $3,636.74 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804113
Principal investigator 1 KYOWA KIRIN, INC. $8,205.61 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804120
Principal investigator 1 KYOWA KIRIN, INC. $4,705.75 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804128
Principal investigator 1 KYOWA KIRIN, INC. $5,268.61 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804137
Principal investigator 1 KYOWA KIRIN, INC. $4,469.01 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804145
Principal investigator 1 KYOWA KIRIN, INC. $6,010.87 04/28/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221804154
Principal investigator 1 Genentech, Inc. $1,303.26 04/25/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599612
Principal investigator 1 Genentech, Inc. $2,287.90 04/23/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599636
Principal investigator 1 Ocular Therapeutix, Inc. $8,470.00 04/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239099
Principal investigator 1 Ocular Therapeutix, Inc. $3,850.00 04/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239101
Principal investigator 1 SANOFI US SERVICES INC. $36,572.15 04/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085552
Principal investigator 1 SANOFI US SERVICES INC. $8,213.20 04/23/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085556
Principal investigator 1 Genentech, Inc. $5,598.74 04/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599609
Principal investigator 1 Genentech, Inc. $28,824.52 04/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599640
Principal investigator 1 Ocular Therapeutix, Inc. $3,000.00 04/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239093
Principal investigator 1 Ocular Therapeutix, Inc. $8,795.00 04/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239095
Principal investigator 1 Ocular Therapeutix, Inc. $29,923.76 04/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239097
Principal investigator 1 Roche TCRC, Inc. $708.00 04/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655878
Principal investigator 1 Roche TCRC, Inc. $103.00 04/18/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655883
Principal investigator 1 Roche TCRC, Inc. $12,400.00 04/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655846
Principal investigator 1 Roche TCRC, Inc. $9,700.00 04/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655887
Principal investigator 1 Ocular Therapeutix, Inc. $6,455.23 04/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239087
Principal investigator 1 Ocular Therapeutix, Inc. $33,663.40 04/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239089
Principal investigator 1 Ocular Therapeutix, Inc. $1,500.00 04/16/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239091
Recipient F. Hoffmann-La Roche AG $644.00 04/14/2025 Covered Recipient Physician A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211534668
Principal investigator 1 Genentech, Inc. $5,480.00 04/11/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599623
Principal investigator 1 Genentech, Inc. $87,003.00 04/11/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599647
Principal investigator 1 Ocular Therapeutix, Inc. $2,310.00 04/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239083
Principal investigator 1 Ocular Therapeutix, Inc. $17,710.00 04/11/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239085
Principal investigator 1 Ocular Therapeutix, Inc. $14,835.72 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239061
Principal investigator 1 Ocular Therapeutix, Inc. $1,500.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239063
Principal investigator 1 Ocular Therapeutix, Inc. $1,500.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239065
Principal investigator 1 Ocular Therapeutix, Inc. $684.40 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239067
Principal investigator 1 Ocular Therapeutix, Inc. $4,500.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239069
Principal investigator 1 Ocular Therapeutix, Inc. $5,234.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239071
Principal investigator 1 Ocular Therapeutix, Inc. $490.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239073
Principal investigator 1 Ocular Therapeutix, Inc. $10,000.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239075
Principal investigator 1 Ocular Therapeutix, Inc. $1,320.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239077
Principal investigator 1 Ocular Therapeutix, Inc. $6,000.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239079
Principal investigator 1 Ocular Therapeutix, Inc. $220.00 04/09/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239081
Principal investigator 1 Genentech, Inc. $3,595.08 04/08/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599651
Principal investigator 1 Genentech, Inc. $7,000.00 04/08/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON COHEN ET
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211599884
Principal investigator 1 Ocular Therapeutix, Inc. $17,758.76 04/04/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239059
Principal investigator 1 Genentech, Inc. $1,500.00 04/03/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON COHEN ET
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211599889
Principal investigator 1 Ocular Therapeutix, Inc. $19,775.00 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239045
Principal investigator 1 Ocular Therapeutix, Inc. $17,500.24 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239047
Principal investigator 1 Ocular Therapeutix, Inc. $14,315.57 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239049
Principal investigator 1 Ocular Therapeutix, Inc. $479.00 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239051
Principal investigator 1 Ocular Therapeutix, Inc. $22,775.00 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239053
Principal investigator 1 Ocular Therapeutix, Inc. $2,980.05 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239055
Principal investigator 1 Ocular Therapeutix, Inc. $23,420.24 04/02/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239057
Principal investigator 1 KYOWA KIRIN, INC. $8,117.25 04/01/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802710
Recipient F. Hoffmann-La Roche AG $937.00 03/31/2025 Covered Recipient Physician Four-Year Outcomes of Faricimab in DME: Safety and Efficacy Results From The RHONE-X Long-Term Extension Trial No dispute reported 06/30/2026 1211534721
Recipient F. Hoffmann-La Roche AG $565.91 03/31/2025 Covered Recipient Physician Clinical Features of Eyes that Participated in the RHONE-X Trial No dispute reported 06/30/2026 1211534725
Recipient F. Hoffmann-La Roche AG $668.00 03/31/2025 Covered Recipient Physician Four-Year Outcomes of Faricimab in DME: First Time Safety and Efficacy Results From The RHONE-X Long-Term Extension Trial No dispute reported 06/30/2026 1211534732
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/31/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427227
Recipient F. Hoffmann-La Roche AG $405.77 03/30/2025 Covered Recipient Physician OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211534685
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239221
Principal investigator 1 Ocular Therapeutix, Inc. $13,338.00 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239223
Principal investigator 1 Ocular Therapeutix, Inc. $8,326.28 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239225
Principal investigator 1 Ocular Therapeutix, Inc. $13,338.00 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239227
Principal investigator 1 Ocular Therapeutix, Inc. $6,418.00 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239229
Principal investigator 1 Ocular Therapeutix, Inc. $215.00 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239231
Principal investigator 1 Ocular Therapeutix, Inc. $20,701.48 03/28/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239233
Principal investigator 1 Genentech, Inc. $200.00 03/27/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599654
Principal investigator 1 Genentech, Inc. $70,392.00 03/26/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599614
Principal investigator 1 Genentech, Inc. $1,425.00 03/26/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599630
Principal investigator 1 Genentech, Inc. $3,609.69 03/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599602
Principal investigator 1 Genentech, Inc. $750.00 03/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599606
Principal investigator 1 Genentech, Inc. $1,686.99 03/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599627
Principal investigator 1 Ocular Therapeutix, Inc. $216,273.60 03/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239219
Principal investigator 1 Genentech, Inc. $14,773.92 03/20/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599643
Principal investigator 1 Genentech, Inc. $11,242.14 03/20/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599816
Principal investigator 1 Genentech, Inc. $1,500.00 03/20/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599821
Principal investigator 1 KYOWA KIRIN, INC. $500.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802309
Principal investigator 1 KYOWA KIRIN, INC. $8,220.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802315
Principal investigator 1 KYOWA KIRIN, INC. $137.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802322
Principal investigator 1 KYOWA KIRIN, INC. $1,500.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802332
Principal investigator 1 KYOWA KIRIN, INC. $10,396.93 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802340
Principal investigator 1 KYOWA KIRIN, INC. $411.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802349
Principal investigator 1 KYOWA KIRIN, INC. $719.25 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802358
Principal investigator 1 KYOWA KIRIN, INC. $10,396.93 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802364
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802371
Principal investigator 1 KYOWA KIRIN, INC. $959.00 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802379
Principal investigator 1 KYOWA KIRIN, INC. $10,396.93 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802386
Principal investigator 1 KYOWA KIRIN, INC. $6,233.50 03/20/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221802396
Principal investigator 1 Ocular Therapeutix, Inc. $343.00 03/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239217
Principal investigator 1 Ocular Therapeutix, Inc. $22,089.48 03/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239215
Principal investigator 1 Genentech, Inc. $150.00 03/13/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON COHEN ET
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211599876
Principal investigator 1 Genentech, Inc. $225.00 03/13/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON COHEN ET
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere) No dispute reported 06/30/2026 1211599881
Principal investigator 1 Genentech, Inc. $21,831.00 03/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655545
Principal investigator 1 Ocular Therapeutix, Inc. $12,956.77 03/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239211
Principal investigator 1 Ocular Therapeutix, Inc. $31,954.50 03/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239213
Principal investigator 1 SANOFI US SERVICES INC. $3,379.68 03/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085532
Principal investigator 1 Roche TCRC, Inc. $1,200.00 03/10/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655860
Principal investigator 1 Genentech, Inc. $204.00 03/07/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655518
Principal investigator 1 Genentech, Inc. $9,772.00 03/07/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655521
Principal investigator 1 Ocular Therapeutix, Inc. $21,878.59 03/07/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239209
Principal investigator 1 KYOWA KIRIN, INC. $137.00 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801712
Principal investigator 1 KYOWA KIRIN, INC. $6,677.93 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801719
Principal investigator 1 KYOWA KIRIN, INC. $4,705.13 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801725
Principal investigator 1 KYOWA KIRIN, INC. $3,809.36 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801731
Principal investigator 1 KYOWA KIRIN, INC. $8,168.63 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801739
Principal investigator 1 KYOWA KIRIN, INC. $102.75 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801748
Principal investigator 1 KYOWA KIRIN, INC. $5,517.67 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801760
Principal investigator 1 KYOWA KIRIN, INC. $3,716.88 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801767
Principal investigator 1 KYOWA KIRIN, INC. $890.50 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801775
Principal investigator 1 KYOWA KIRIN, INC. $3,482.61 03/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221801782
Principal investigator 1 Ocular Therapeutix, Inc. $891.00 03/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239203
Principal investigator 1 Ocular Therapeutix, Inc. $9,236.38 03/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239205
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 03/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239207
Principal investigator 1 Janssen Research & Development, LLC $11,284.00 03/03/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427296
Principal investigator 1 SANOFI US SERVICES INC. $19,237.00 03/03/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085536
Principal investigator 1 Genentech, Inc. $68.00 02/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655495
Principal investigator 1 Genentech, Inc. $81.00 02/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655505
Principal investigator 1 Genentech, Inc. $1,095.00 02/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655529
Principal investigator 1 Genentech, Inc. $812.00 02/26/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655536
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 02/25/2025 Non-covered Recipient Entity
Sierra Eye Associates
Age-related macular degeneration No dispute reported 06/30/2026 1226085528
Principal investigator 1 Janssen Research & Development, LLC $1,060.00 02/24/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427205
Principal investigator 1 Roche TCRC, Inc. $1,200.00 02/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655863
Principal investigator 1 Roche TCRC, Inc. $1,500.00 02/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655875
Principal investigator 1 Genentech, Inc. $33,113.28 02/19/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599808
Principal investigator 1 Ocular Therapeutix, Inc. $8,290.24 02/19/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239039
Principal investigator 1 Genentech, Inc. $1,303.26 02/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599558
Principal investigator 1 Genentech, Inc. $25,196.36 02/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599578
Principal investigator 1 Genentech, Inc. $6,871.68 02/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599599
Principal investigator 1 Genentech, Inc. $124,137.00 02/18/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599798
Principal investigator 1 KYOWA KIRIN, INC. $685.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800882
Principal investigator 1 KYOWA KIRIN, INC. $1,781.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800891
Principal investigator 1 KYOWA KIRIN, INC. $205.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800899
Principal investigator 1 KYOWA KIRIN, INC. $9,247.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800907
Principal investigator 1 KYOWA KIRIN, INC. $3,318.14 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800912
Principal investigator 1 KYOWA KIRIN, INC. $9,247.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800922
Principal investigator 1 KYOWA KIRIN, INC. $9,316.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800926
Principal investigator 1 KYOWA KIRIN, INC. $4,126.44 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800933
Principal investigator 1 KYOWA KIRIN, INC. $2,740.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800941
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800949
Principal investigator 1 KYOWA KIRIN, INC. $4,544.29 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800957
Principal investigator 1 KYOWA KIRIN, INC. $205.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800963
Principal investigator 1 KYOWA KIRIN, INC. $2,740.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800972
Principal investigator 1 KYOWA KIRIN, INC. $274.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800980
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800987
Principal investigator 1 KYOWA KIRIN, INC. $68.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800991
Principal investigator 1 KYOWA KIRIN, INC. $9,247.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801000
Principal investigator 1 KYOWA KIRIN, INC. $560.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801006
Principal investigator 1 KYOWA KIRIN, INC. $1,781.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801011
Principal investigator 1 KYOWA KIRIN, INC. $274.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801019
Principal investigator 1 KYOWA KIRIN, INC. $5,343.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801026
Principal investigator 1 KYOWA KIRIN, INC. $2,740.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801033
Principal investigator 1 KYOWA KIRIN, INC. $137.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801040
Principal investigator 1 KYOWA KIRIN, INC. $137.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801047
Principal investigator 1 KYOWA KIRIN, INC. $2,740.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801054
Principal investigator 1 KYOWA KIRIN, INC. $137.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801062
Principal investigator 1 KYOWA KIRIN, INC. $50.91 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801070
Principal investigator 1 KYOWA KIRIN, INC. $616.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801077
Principal investigator 1 KYOWA KIRIN, INC. $274.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801085
Principal investigator 1 KYOWA KIRIN, INC. $822.00 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801094
Principal investigator 1 KYOWA KIRIN, INC. $68.50 02/14/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221801100
Principal investigator 1 Ocular Therapeutix, Inc. $141,079.50 02/14/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239037
Principal investigator 1 Janssen Research & Development, LLC $1,365.00 02/13/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427145
Principal investigator 1 Genentech, Inc. $1,400.00 02/12/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655533
Principal investigator 1 Ocular Therapeutix, Inc. $31,605.59 02/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239031
Principal investigator 1 Ocular Therapeutix, Inc. $3,371.24 02/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239033
Principal investigator 1 Ocular Therapeutix, Inc. $46,682.00 02/12/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239035
Principal investigator 1 Alexion Pharmaceuticals, Inc. $70,050.35 02/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) No dispute reported 06/30/2026 1185549157
Principal investigator 1 Genentech, Inc. $770.00 02/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655491
Principal investigator 1 Genentech, Inc. $68.00 02/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655514
Principal investigator 1 Genentech, Inc. $13,669.00 02/05/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655526
Principal investigator 1 Ocular Therapeutix, Inc. $32,380.20 02/05/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239025
Principal investigator 1 Genentech, Inc. $6,000.00 02/04/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD No dispute reported 06/30/2026 1211599473
Principal investigator 1 Janssen Research & Development, LLC $14,154.00 02/03/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427279
Principal investigator 1 Janssen Research & Development, LLC $1,260.00 02/03/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427308
Principal investigator 1 Janssen Research & Development, LLC $9,500.00 01/31/2025 Non-covered Recipient Entity
DURANT ET AL
Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies No dispute reported 06/30/2026 1175427192
Principal investigator 1 KYOWA KIRIN, INC. $137.00 01/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221800635
Principal investigator 1 KYOWA KIRIN, INC. $68.50 01/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221800641
Principal investigator 1 KYOWA KIRIN, INC. $890.50 01/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221800650
Principal investigator 1 KYOWA KIRIN, INC. $102.75 01/30/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221800654
Principal investigator 1 Ocular Therapeutix, Inc. $3,919.24 01/29/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239043
Principal investigator 1 Genentech, Inc. $6,633.04 01/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211599562
Principal investigator 1 Genentech, Inc. $6,898.84 01/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211599566
Principal investigator 1 Genentech, Inc. $1,401.33 01/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599594
Principal investigator 1 Genentech, Inc. $42,886.08 01/28/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
MAD to assess the safety tolerability and PK PD in nAMD patients No dispute reported 06/30/2026 1211599803
Principal investigator 1 KYOWA KIRIN, INC. $5,327.79 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799922
Principal investigator 1 KYOWA KIRIN, INC. $205.50 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799930
Principal investigator 1 KYOWA KIRIN, INC. $4,538.67 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799941
Principal investigator 1 KYOWA KIRIN, INC. $890.50 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799948
Principal investigator 1 KYOWA KIRIN, INC. $137.00 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799964
Principal investigator 1 KYOWA KIRIN, INC. $137.00 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799968
Principal investigator 1 KYOWA KIRIN, INC. $5,105.85 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799977
Principal investigator 1 KYOWA KIRIN, INC. $5,426.43 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221799999
Principal investigator 1 KYOWA KIRIN, INC. $137.00 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800007
Principal investigator 1 KYOWA KIRIN, INC. $2,740.00 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800016
Principal investigator 1 KYOWA KIRIN, INC. $7,238.94 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800023
Principal investigator 1 KYOWA KIRIN, INC. $8,322.75 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800041
Principal investigator 1 KYOWA KIRIN, INC. $890.50 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800049
Principal investigator 1 KYOWA KIRIN, INC. $137.00 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800057
Principal investigator 1 KYOWA KIRIN, INC. $5,105.85 01/27/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1221800062
Principal investigator 1 Genentech, Inc. $77,283.00 01/24/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655501
Principal investigator 1 Ocular Therapeutix, Inc. $4,193.24 01/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239041
Principal investigator 1 Roche TCRC, Inc. $163.64 01/24/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655871
Principal investigator 1 Ocular Therapeutix, Inc. $2,000.00 01/22/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239027
Principal investigator 1 Ocular Therapeutix, Inc. $3,097.24 01/22/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239029
Principal investigator 1 Genentech, Inc. $1,583.15 01/21/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599581
Principal investigator 1 Roche TCRC, Inc. $45,114.00 01/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
PHASE 2 STUDY TO INVESTIGATE RO7200220 IN DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211655835
Principal investigator 1 Roche TCRC, Inc. $32,421.00 01/21/2025 Non-covered Recipient Entity
Sierra Eye Associates
A STUDY TO INVESTIGATE RO7200394 AS NOVEL INTRAVITREAL TREATMENT FOR CENTRAL RETINAL VEIN OCCLUSION No dispute reported 06/30/2026 1211655867
Recipient Novartis Pharmaceuticals Corporation $2,168.50 01/17/2025 Covered Recipient Physician CRTH258A2301 No dispute reported 06/30/2026 1190292741
Principal investigator 1 Ocular Therapeutix, Inc. $3,234.24 01/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239021
Principal investigator 1 Ocular Therapeutix, Inc. $3,175.24 01/17/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239023
Principal investigator 1 Genentech, Inc. $5,323.71 01/14/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599574
Principal investigator 1 Ocular Therapeutix, Inc. $1,000.00 01/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239017
Principal investigator 1 Ocular Therapeutix, Inc. $2,706.05 01/13/2025 Non-covered Recipient Entity
Sierra Eye Associates
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250239019
Principal investigator 1 Genentech, Inc. $2,688.11 01/10/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599571
Principal investigator 1 Genentech, Inc. $259.62 01/10/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599586
Principal investigator 1 Genentech, Inc. $1,392.07 01/10/2025 Non-covered Recipient Entity
DURANT STANKO JOHNSON + COHEN PC SIERRA EYE ASSOC
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211599590
Principal investigator 1 Novartis Pharmaceuticals Corporation $40,920.95 01/10/2025 Non-covered Recipient Entity
DURANT ET AL SIERRA EYE ASSOCIATES
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study No dispute reported 06/30/2026 1190305073
Principal investigator 1 Janssen Research & Development, LLC $150.00 01/09/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427155
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 01/09/2025 Non-covered Recipient Entity
DURANT ET AL
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular No dispute reported 06/30/2026 1175427273
Principal investigator 1 KYOWA KIRIN, INC. $1,000.00 01/08/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221798844
Principal investigator 1 KYOWA KIRIN, INC. $340.62 01/08/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION No dispute reported 06/30/2026 1221798852
Principal investigator 1 Genentech, Inc. $6,217.00 01/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655498
Principal investigator 1 Genentech, Inc. $720.00 01/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
Faricimab for Under represented Patients with DME No dispute reported 06/30/2026 1211655509
Principal investigator 1 Genentech, Inc. $973.00 01/03/2025 Non-covered Recipient Entity
SIERRA EYE ASSOCIATES
iAMD Observational Study No dispute reported 06/30/2026 1211655540